Ascendis Pharma A/S (NASDAQ:ASND) Price Target Cut to $153.00 by Analysts at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective dropped by equities researchers at TD Cowen from $160.00 to $153.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. TD Cowen’s target price points to a potential upside of 17.80% from the company’s previous close.

Several other equities research analysts have also weighed in on ASND. Evercore ISI lifted their price target on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group increased their price target on shares of Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Wedbush restated an “outperform” rating and issued a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday. Finally, Citigroup raised their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Stock Performance

ASND traded up $5.60 during trading on Friday, reaching $129.88. The stock had a trading volume of 954,802 shares, compared to its average volume of 447,905. The business has a 50-day moving average of $132.15 and a 200-day moving average of $132.80. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00. The stock has a market cap of $7.88 billion, a PE ratio of -13.95 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Equities research analysts forecast that Ascendis Pharma A/S will post -7.35 EPS for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of ASND. Price T Rowe Associates Inc. MD raised its stake in Ascendis Pharma A/S by 23.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Ascendis Pharma A/S by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock valued at $1,664,000 after acquiring an additional 4,338 shares during the last quarter. Evolutionary Tree Capital Management LLC grew its position in Ascendis Pharma A/S by 82.3% in the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after acquiring an additional 11,223 shares in the last quarter. SG Americas Securities LLC grew its position in Ascendis Pharma A/S by 221.0% in the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after acquiring an additional 4,205 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Ascendis Pharma A/S by 1,461.1% during the first quarter. Acadian Asset Management LLC now owns 250,492 shares of the biotechnology company’s stock worth $37,849,000 after acquiring an additional 234,446 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.